INTRODUCTION: Causes of treatment failure in acute lymphoblastic leukemia (ALL) are still poorly understood. Microarray technology gives new possibilities for the analysis of the biology of leukemias. We hypothesize that drug sensitivity in pediatric ALL is driven by specific molecular mechanisms that correlate with gene expression profiles assessed by microarray analysis. OBJECTIVE: The aim of the study was to determine the ex vivo resistance profiles of 20 antileukemic drugs and gene expression profiles, with relation to response to initial therapy. PATIENTS AND METHODS: Lymphoblasts were analyzed after bone marrow biopsy was obtained from 56 patients. The profile of in vitro resistance to drugs was determined in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) cytotoxicity assay. High-quality total RNA was prepared and hybridized to oligonucleotide arrays HG-U133A 2.0 Chip (Affymetrix). The expression of selected genes was tested by qualitative reverse transcription polymerase chain reaction (qRT-PCR). RESULTS AND CONCLUSIONS: The exposure of leukemic blasts to drugs initiates a complex cellular response, which reflects global changes in gene expression. Changes in the expression of several genes are highly correlated with drug resistance.
INTRODUCTION: Causes of treatment failure in acute lymphoblastic leukemia (ALL) are still poorly understood. Microarray technology gives new possibilities for the analysis of the biology of leukemias. We hypothesize that drug sensitivity in pediatric ALL is driven by specific molecular mechanisms that correlate with gene expression profiles assessed by microarray analysis. OBJECTIVE: The aim of the study was to determine the ex vivo resistance profiles of 20 antileukemic drugs and gene expression profiles, with relation to response to initial therapy. PATIENTS AND METHODS: Lymphoblasts were analyzed after bone marrow biopsy was obtained from 56 patients. The profile of in vitro resistance to drugs was determined in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) cytotoxicity assay. High-quality total RNA was prepared and hybridized to oligonucleotide arrays HG-U133A 2.0 Chip (Affymetrix). The expression of selected genes was tested by qualitative reverse transcription polymerase chain reaction (qRT-PCR). RESULTS AND CONCLUSIONS: The exposure of leukemic blasts to drugs initiates a complex cellular response, which reflects global changes in gene expression. Changes in the expression of several genes are highly correlated with drug resistance.
Authors: Sanne Lugthart; Meyling H Cheok; Monique L den Boer; Wenjian Yang; Amy Holleman; Cheng Cheng; Ching-Hon Pui; Mary V Relling; Gritta E Janka-Schaub; Rob Pieters; William E Evans Journal: Cancer Cell Date: 2005-04 Impact factor: 31.743
Authors: M L den Boer; R Pieters; K M Kazemier; M M Rottier; C M Zwaan; G J Kaspers; G Janka-Schaub; G Henze; U Creutzig; R J Scheper; A J Veerman Journal: Blood Date: 1998-03-15 Impact factor: 22.113
Authors: Anja Möricke; Alfred Reiter; Martin Zimmermann; Helmut Gadner; Martin Stanulla; Michael Dördelmann; Lutz Löning; Rita Beier; Wolf-Dieter Ludwig; Richard Ratei; Jochen Harbott; Joachim Boos; Georg Mann; Felix Niggli; Andreas Feldges; Günter Henze; Karl Welte; Jörn-Dirk Beck; Thomas Klingebiel; Charlotte Niemeyer; Felix Zintl; Udo Bode; Christian Urban; Helmut Wehinger; Dietrich Niethammer; Hansjörg Riehm; Martin Schrappe Journal: Blood Date: 2008-02-19 Impact factor: 22.113
Authors: Eduardo Vilar; Bhramar Mukherjee; Rork Kuick; Leon Raskin; David E Misek; Jeremy M G Taylor; Thomas J Giordano; Samir M Hanash; Eric R Fearon; Gad Rennert; Stephen B Gruber Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: Dieter Hoelzer; Nicola Gökbuget; Oliver Ottmann; Ching-Hon Pui; Mary V Relling; Frederick R Appelbaum; Jacques J M van Dongen; Tomasz Szczepański Journal: Hematology Am Soc Hematol Educ Program Date: 2002
Authors: Adolfo A Ferrando; Donna S Neuberg; Jane Staunton; Mignon L Loh; Christine Huard; Susana C Raimondi; Fred G Behm; Ching Hon Pui; James R Downing; D Gary Gilliland; Eric S Lander; Todd R Golub; A Thomas Look Journal: Cancer Cell Date: 2002-02 Impact factor: 31.743
Authors: Stefano Ratti; Camilla Evangelisti; Sara Mongiorgi; Alessia De Stefano; Antonietta Fazio; Francesca Bonomini; Matilde Y Follo; Irene Faenza; Lucia Manzoli; Bhavwanti Sheth; Magdalena C Vidalle; Scott T Kimber; Nullin Divecha; Lucio Cocco; Roberta Fiume Journal: Front Oncol Date: 2021-05-24 Impact factor: 6.244
Authors: Nullin Divecha; Tim C P Somervaille; Julian G Jude; Gary J Spencer; Xu Huang; Tim D D Somerville; David R Jones Journal: Oncogene Date: 2014-03-31 Impact factor: 9.867